• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

仅加速清除即可解释威伦堡病 Vicenza 的超大多聚体。

Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.

机构信息

Central Immunology Laboratory, Semmelweis University, Budapest, Hungary.

出版信息

J Thromb Haemost. 2010 Jun;8(6):1273-80. doi: 10.1111/j.1538-7836.2010.03753.x. Epub 2010 Jan 17.

DOI:10.1111/j.1538-7836.2010.03753.x
PMID:20088930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3863617/
Abstract

BACKGROUND

von Willebrand disease (VWD) Vicenza is characterized by low plasma von Willebrand factor (VWF) levels, the presence of ultra-large (UL) VWF multimers and less prominent satellite bands on multimer gels, and the heterozygous amino acid substitution R1205H in the VWF gene. The pathogenesis of VWD Vicenza has been elusive. Accelerated clearance is implicated as a cause of low VWF level.

OBJECTIVES

We addressed the question, whether the presence of ultra-large multimers is a cause, or a result of accelerated VWF clearance, or whether it is an unrelated phenomenon.

PATIENTS/METHODS: We studied the detailed phenotype of three Hungarian patients with VWD Vicenza, expressed the mutant VWF-R1205H in 293T cells and developed a mathematical model to simulate VWF synthesis and catabolism.

RESULTS

We found that the half-life of VWF after DDAVP was approximately one-tenth of that after the administration of Haemate P, a source of exogenous wild-type (WT) VWF (0.81 + or - 0.2 vs. 7.25 + or - 2.38 h). An analysis of recombinant mutant VWF-R1205H showed that the biosynthesis and multimer structure of WT and mutant VWF were indistinguishable. A mathematical model of the complex interplay of VWF synthesis, clearance and cleavage showed that decreasing VWF half-life to one-tenth of normal reproduced all features of VWD Vicenza including low VWF level, ultra-large multimers and a decrease of satellite band intensity.

CONCLUSION

We conclude that accelerated clearance alone may explain all features of VWD Vicenza.

摘要

背景

血管性血友病(VWD)Vicenza 的特点是血浆血管性血友病因子(VWF)水平降低,存在超大(UL)VWF 多聚体,多聚体凝胶上卫星带不明显,VWF 基因存在杂合氨基酸取代 R1205H。VWD Vicenza 的发病机制一直难以捉摸。加速清除被认为是 VWF 水平降低的原因。

目的

我们探讨了超大多聚体的存在是加速 VWF 清除的原因、结果还是无关现象。

患者/方法:我们研究了三名匈牙利 VWD Vicenza 患者的详细表型,在 293T 细胞中表达突变型 VWF-R1205H,并开发了一个数学模型来模拟 VWF 的合成和代谢。

结果

我们发现 DDAVP 后 VWF 的半衰期大约是 Haemate P(外源性野生型(WT)VWF 的来源)后半衰期的十分之一(0.81 +或-0.2 与 7.25 +或-2.38 h)。对重组突变型 VWF-R1205H 的分析表明,WT 和突变型 VWF 的生物合成和多聚体结构无法区分。VWF 合成、清除和裂解复杂相互作用的数学模型表明,将 VWF 半衰期降低至正常的十分之一可重现 VWD Vicenza 的所有特征,包括 VWF 水平降低、超大多聚体和卫星带强度降低。

结论

我们得出结论,仅加速清除就可以解释 VWD Vicenza 的所有特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/91530b956e44/nihms528246f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/7d05fcad4c67/nihms528246f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/3d34a86ec554/nihms528246f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/0a779b43acb2/nihms528246f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/aceefe417958/nihms528246f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/91530b956e44/nihms528246f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/7d05fcad4c67/nihms528246f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/3d34a86ec554/nihms528246f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/0a779b43acb2/nihms528246f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/aceefe417958/nihms528246f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3211/3863617/91530b956e44/nihms528246f5.jpg

相似文献

1
Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.仅加速清除即可解释威伦堡病 Vicenza 的超大多聚体。
J Thromb Haemost. 2010 Jun;8(6):1273-80. doi: 10.1111/j.1538-7836.2010.03753.x. Epub 2010 Jan 17.
2
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.1型/2E型(2A亚型IIE)血管性血友病、1型维琴察型血管性血友病以及由血管性血友病因子基因的D3、D4、B1 - B3和C1 - C2结构域突变引起的轻型1型血管性血友病的实验室诊断。血管性血友病因子多聚体及血管性血友病因子前肽/抗原比值的作用。
Acta Haematol. 2009;121(2-3):128-38. doi: 10.1159/000214853. Epub 2009 Jun 8.
3
Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival.维琴察型血管性血友病:探寻血管性血友病因子生存减少原型的分类方法。
EJHaem. 2021 May 5;2(3):340-348. doi: 10.1002/jha2.196. eCollection 2021 Aug.
4
Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.2M型血管性血友病患者使用去氨加压素后及孕期因子VIII和血管性血友病因子的变化:维琴察的一项前瞻性研究,比较单一缺陷(R1205H)和双重缺陷(R1205H - M740I)的患者
J Thromb Haemost. 2006 Feb;4(2):357-60. doi: 10.1111/j.1538-7836.2006.01706.x.
5
Laboratory diagnosis and molecular classification of von Willebrand disease.血管性血友病的实验室诊断与分子分类
Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8.
6
Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.2A型和2B型血管性血友病变异体中血管性血友病因子寡聚体的不同组织形式:去氨加压素输注和蛋白酶抑制剂的作用
Ann Hematol. 1995 Oct;71(4):189-94. doi: 10.1007/BF01910317.
7
Identifying type Vicenza von Willebrand disease.识别维琴察型血管性血友病。
J Lab Clin Med. 2006 Feb;147(2):96-102. doi: 10.1016/j.lab.2005.10.002.
8
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.维琴察型血管性血友病因子生存时间缩短。
Blood. 2002 Jan 1;99(1):180-4. doi: 10.1182/blood.v99.1.180.
9
Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease.不同类型血管性血友病中血管性血友病因子二聚化缺陷的表达与特征分析
Blood. 2001 Apr 1;97(7):2059-66. doi: 10.1182/blood.v97.7.2059.
10
The genetic defect of type I von Willebrand disease "Vicenza" is linked to the von Willebrand factor gene.I型血管性血友病“维琴察型”的基因缺陷与血管性血友病因子基因有关。
Thromb Haemost. 1993 Feb 1;69(2):173-6.

引用本文的文献

1
Patient-reported data on the severity of Von Willebrand disease.患者报告的血管性血友病严重程度数据。
Haemophilia. 2024 Nov;30(6):1348-1356. doi: 10.1111/hae.15103. Epub 2024 Oct 15.
2
R1205H (Vicenza) causes conformational changes in the von Willebrand factor D'D3 domains and enhances von Willebrand factor binding to clearance receptors LRP1 and SR-AI.R1205H(Vicenza)导致血管性血友病因子 D'D3 结构域发生构象变化,并增强血管性血友病因子与清除受体 LRP1 和 SR-AI 的结合。
J Thromb Haemost. 2024 Oct;22(10):2752-2760. doi: 10.1016/j.jtha.2024.06.023. Epub 2024 Jul 10.
3
Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival.维琴察型血管性血友病:探寻血管性血友病因子生存减少原型的分类方法。
EJHaem. 2021 May 5;2(3):340-348. doi: 10.1002/jha2.196. eCollection 2021 Aug.
4
Diagnosing von Willebrand disease: genetic analysis.诊断血管性血友病:基因分析
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):678-682. doi: 10.1182/asheducation-2016.1.678.
5
A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.来自670个患有血管性血友病家庭的1167名法国患者的实验室表型/基因型相关性:一种新的流行病学情况。
Medicine (Baltimore). 2016 Mar;95(11):e3038. doi: 10.1097/MD.0000000000003038.
6
New insights into genotype and phenotype of VWD.血管性血友病(VWD)基因型和表型的新见解。
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):531-5. doi: 10.1182/asheducation-2014.1.531. Epub 2014 Nov 18.
7
von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.血管性血友病:大型血管性血友病研究中获得的临床和实验室经验教训。
Am J Hematol. 2012 May;87 Suppl 1(0 1):S4-11. doi: 10.1002/ajh.23142. Epub 2012 Mar 3.
8
Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.通过体外和体内小鼠模型研究 1 型 VWD 突变 R1205H 和 Y1584C 的病理机制。
Blood. 2011 Apr 21;117(16):4358-66. doi: 10.1182/blood-2010-08-303727. Epub 2011 Feb 23.

本文引用的文献

1
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).在欧洲研究中通过检测血管性血友病因子原肽鉴定血管性血友病因子生存期缩短的1型血管性血友病患者:1型血管性血友病(MCMDM-1VWD)诊断和管理的分子及临床标志物
Blood. 2008 May 15;111(10):4979-85. doi: 10.1182/blood-2007-09-110940. Epub 2008 Mar 14.
2
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.1型血管性血友病(VWD)中去氨加压素的反应受基因型和表型影响:欧洲MCMDM-1VWD研究结果
Blood. 2008 Apr 1;111(7):3531-9. doi: 10.1182/blood-2007-08-109231. Epub 2008 Jan 29.
3
Clearance mechanisms of von Willebrand factor and factor VIII.血管性血友病因子和凝血因子VIII的清除机制。
J Thromb Haemost. 2007 Jul;5(7):1353-60. doi: 10.1111/j.1538-7836.2007.02572.x. Epub 2007 Apr 7.
4
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.血管性血友病的病理生理学与分类更新:血管性血友病因子小组委员会报告
J Thromb Haemost. 2006 Oct;4(10):2103-14. doi: 10.1111/j.1538-7836.2006.02146.x. Epub 2006 Aug 2.
5
Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.检测血管性血友病因子(VWF)前肽以识别血管性血友病1型且VWF生存期缩短的患者。
Blood. 2006 Nov 15;108(10):3344-51. doi: 10.1182/blood-2006-04-015065. Epub 2006 Jul 11.
6
Identifying type Vicenza von Willebrand disease.识别维琴察型血管性血友病。
J Lab Clin Med. 2006 Feb;147(2):96-102. doi: 10.1016/j.lab.2005.10.002.
7
Cysteine-mutations in von Willebrand factor associated with increased clearance.血管性血友病因子中的半胱氨酸突变与清除率增加相关。
J Thromb Haemost. 2005 Oct;3(10):2228-37. doi: 10.1111/j.1538-7836.2005.01571.x.
8
An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation.一种用于研究血管性血友病因子体内存活情况的实验模型。基本方面及R1205H突变的应用。
J Biol Chem. 2004 Mar 26;279(13):12102-9. doi: 10.1074/jbc.M310436200. Epub 2003 Nov 12.
9
Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?1型血管性血友病患者去氨加压素治疗后血管性血友病因子抗原清除增加:这是一个潜在的致病过程吗?
J Thromb Haemost. 2003 Aug;1(8):1714-7. doi: 10.1046/j.1538-7836.2003.00359.x.
10
The elusive pathogenesis of von Willebrand disease Vicenza.维琴察血管性血友病的难以捉摸的发病机制。
Blood. 2002 Jun 1;99(11):4243-4; author reply 4244. doi: 10.1182/blood.v99.11.4243.